Tylon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-11-2024
- Paid Up Capital ₹ 0.70 M
as on 08-11-2024
- Company Age 2 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.30 Cr
as on 08-11-2024
About Tylon Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M.
The company currently has active open charges totaling ₹2.30 Cr.
Indrakumar Tiwari, Rajkumari Tiwari, and Devendraprasad Tiwari serve as directors at the Company.
- CIN/LLPIN
U52609MH2022PLC390911
- Company No.
390911
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2022
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tylon Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Indrakumar Tiwari  | Director | 21-Sep-2022 | Current |
| Rajkumari Tiwari | Director | 21-Sep-2022 | Current |
| Devendraprasad Tiwari | Additional Director | 04-May-2023 | Current |
Financial Performance of Tylon Pharma.
Tylon Pharma Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Tylon Pharma?
In 2023, Tylon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Asmee Chemicals Private LimitedActive 8 years 4 monthsIndrakumar Tiwari and Rajkumari Tiwari are mutual person
Chemphar Organic (India) Pvt LtdActive 33 years 6 monthsIndrakumar Tiwari and Rajkumari Tiwari are mutual person
- Indo Oxygen Private LimitedActive 14 years 4 months
Indrakumar Tiwari and Rajkumari Tiwari are mutual person
- Chemphar Pharmaceuticals Private LimitedActive 2 years 4 months
Indrakumar Tiwari and Rajkumari Tiwari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 31 Jul 2023 | ₹2.30 Cr | Open |
How Many Employees Work at Tylon Pharma?
Tylon Pharma has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tylon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tylon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
